Users

stories:

interview

with

Douglas

Dieterich

Before VCTE™ and CAP™, the only real diagnostic option for assessing patients with hepatitis C virus was biopsy, and even then, we couldn’t always pick up ‘borderline’ cases. We’ve almost stopped doing biopsies now, except in rare diagnostic dilemmas.

Douglas Dieterich| M.D., Professor of Medicine at Mount Sinai Health System, division of liver disease, New York, USA

How does FibroScan^® complement the assessment of liver disease at Mount Sinai?

Our

goal

provide

the

highest

level

liver

care

across

the

Mount

Sinai

System,

and

FibroScan

^®

integral

part

our

strategy.

FibroScan

^®

has

dramatically

changed

the

way

practice-for

the

better.

has

had

significant

impact

our

patients’

overall

long-term

treatment.

use

opportunity

make

recommendations

for

prognosis

and

testing.

also

great

way

provide

immediate

reinforcement

for

patients.

can

say,

“your

liver

looks

good”,

and

give

them

out

bring

back

their

PCP.

don’t

have

wait

three

days

for

blood

tests

come

back

give

them

idea

how

their

liver

looks.

When is a FibroScan^® exam indicated and how often do you use the device?

We’re

using

FibroScan

^®

for

every

patient

with

liver

disease.

Once

you

have

FibroScan

^®

you

start

thinking

and

ways

use

it.

FibroScan

^®

incredibly

fast

and

useful.

Minutes

after

enter

the

exam

room,

know

the

state

patient’s

liver

disease:

have

better

understanding

fibrosis

and

the

amount

fat

the

liver.

How has FibroScan^® changed the way your physicians and physician assistants assess livers?

Before

VCTE

™

and

CAP

™

the

only

real

diagnostic

option

for

assessing

patients

with

hepatitis

virus

was

biopsy,

and

even

then,

couldn’t

always

pick

‘borderline’

cases.

We’ve

almost

stopped

doing

biopsies

now,

except

rare

diagnostic

dilemmas.

Do you see an impact in being able to screen earlier in a non-invasive exam?

Yes.

The

baby

boomer

cohort

increasingly

presenting

with

sicker

livers.

really

becomes

important

know

their

level

fibrosis.

Even

with

stage

fibrosis,

patients

can

at-risk

for

liver

cancer.

are

now

beginning

scan

patients

the

diabetes

clinic

for

HCV.

Early

detection

critical,

but

found

that

there

inadequate

screening

for

HCV

and

NAFLD

primary

care

settings.

are

using

the

availability

the

FibroScan

^®

technology

encourage

screening

for

liver

diseases.

We’re

putting

portable

unit

into

the

diabetes

clinic

and

have

just

begun

program

screen

every

patient

the

obesity

clinic,

using

FibroScan

^®

How does the dual-function capability of FibroScan^® with VCTE™ and CAP™ affect your approach?

addition

the

liver

stiffness

quantification

with

the

VCTE

™

think

it’s

important

track

CAP

™

well.

The

score

surrogate

marker

for

the

amount

fat

present

the

liver.

What

have

learned

that

patients

who

are

cured

hepatitis

have

dramatic

reductions

their

fibrosis

levels

measured

VCTE

™

However,

those

who

also

have

fatty

liver

disease

frequently

will

not

improve

even

after

viral

response.

Does FibroScan^® have any effect on how you manage patients over the long term?

The

ability

collect

and

track

VCTE

™

and

CAP

™

measurements

allows

our

practice

remain

involved

with

these

patients

throughout

their

liver

care.

It’s

difficult

for

community

doctor

understand

and

monitor

fatty

liver.

And

today,

even

than

hepatitis,

fatty

liver

contributing

cirrhosis

and

liver

cancer.

Even

patient’s

first

visit…

see

CAP

™

over

300,

know

probably

have

this

patient

for

life.

The

first

step

diet

and

exercise

program

for

diabetes.

When

treat

and

cure

HCV

these

patients,

the

fatty

liver

seems

prevent

resolution

the

fibrosis

measured

FibroScan

^®

What does the future look like for you?

Today,

our

Liver

Service

growing

expand

outreach.

feel

it’s

imperative

have

FibroScan

^®

all

our

clinics.

We’ve

purchased

several

portable

units

about

the

size

carry

–

suitcase

that

our

providers

can

travel

with

our

outlying

clinics.

They

have

proven

incredibly

useful.

Patients

still

visit

multiple

clinics

can

bring

the

liver

specialist

the

diabetes

and

obesity

clinics

see

improved

adherence

care.

That’s

something

learned

from

the

HIV

world.

Uncover the clinical evidence

Country*
Email*
By subscribing, I agree that Echosens collects and uses my data in accordance with the Privacy Policy.
Name
This field is for validation purposes and should be left unchanged.

Users stories: interview with Douglas Dieterich

Always be informed about liver health

Users

stories:

interview

with

Douglas

Dieterich